Search

Displaying results 1721 - 1730 of 8468 in total
  1. Drug

    Egg phospholipids

    go.drugbank.com/drugs/DB14233
    ApprovedWithdrawn

    Egg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.

  2. Drug

    Coal tar

    go.drugbank.com/drugs/DB11082
    Approved

    Coal tars are complex and variable mixtures of phenols, polycyclic aromatic hydrocarbons (PAHs), and heterocyclic compounds. … Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas.

    Products: Euro Oil, Euro Oil Forte
  3. Drug

    Atovaquone

    go.drugbank.com/drugs/DB01117
    ApprovedInvestigational

    Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

  4. Drug

    Levonordefrin

    go.drugbank.com/drugs/DB06707
    ApprovedInvestigational

    Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.

  5. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  6. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina. Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.

  7. Drug

    Trolamine salicylate

    go.drugbank.com/drugs/DB11079
    Approved

    Unlike other topical analgesics, trolamine salicylate has no distinct odor which improves patient acceptability [A32189]. … It also displays low systemic absorption upon dermal or topical administration [A32190] and has low skin irritant properties [A32191].

  8. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.

  9. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [

  10. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … [A263126] Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease.